5-[2-[1-(6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5-[2-[1-(6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
• 化学式: C₂₈H₄₄O₃
• 分子量: 428.6
• InChiKey: ZGLHBRQAEXKACO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• COMBINED THERAPY COMPRISING AN INHIBITOR OF INTERLEUKIN-17 ACTIVITY AND A VITAMIN D RECEPTOR AGONIST
  申请人：Servei de Salut de Les Illes Balears - Ibsalut

  公开号：EP3797779A1

  公开（公告）日：2021-03-31

  The invention relates to a combined therapy including an inhibitor of interleukin-17 (IL-17) activity for use in combination with a vitamin D receptor agonist in the prevention and/or treatment of diseases or conditions known as autoimmune and autoinflammatory concomitant diseases, such as autoimmune kidney diseases, autoimmune joint diseases, skin autoimmune diseases, autoimmune neurological diseases, autoimmune thyroid diseases, and gout disease. The invention provides also the combination for use in the treatment and/or prevention of cancer, in which deregulation of immune system takes place. The invention also relates to the therapeutic combination and to its use in the treatment or prevention of proteinuria.

  本发明涉及一种联合疗法，包括一种白细胞介素-17（IL-17）活性抑制剂，用于与维生素D受体激动剂联合使用，预防和/或治疗被称为自身免疫和自身炎症并发症的疾病或病症，如自身免疫性肾脏疾病、自身免疫性关节疾病、皮肤自身免疫性疾病、自身免疫性神经系统疾病、自身免疫性甲状腺疾病和痛风病。本发明还提供了用于治疗和/或预防免疫系统失调的癌症的组合物。本发明还涉及治疗组合物及其在治疗或预防蛋白尿中的用途。
• [EN] COMBINED THERAPY COMPRISING AN INHIBITOR OF INTERLEUKIN-17 ACTIVITY AND A VITAMIN D RECEPTOR AGONIST<br/>[FR] POLYTHÉRAPIE COMPRENANT UN INHIBITEUR DE L'ACTIVITÉ DE L'INTERLEUKINE-17 ET UN AGONISTE DU RÉCEPTEUR DE LA VITAMINE D
  申请人：SERVEI DE SALUT DE LES ILLES BALEARS – IBSALUT

  公开号：WO2021063945A1

  公开（公告）日：2021-04-08

  The invention relates to a combined therapy including an inhibitor of interleukin-17 (IL-17) activity for use in combination with a vitamin D receptor agonist in the prevention and/or treatment of diseases or conditions known as autoimmune and autoinflammatory concomitant diseases, such as autoimmune kidney diseases, autoimmune joint diseases, skin autoimmune diseases, autoimmune neurological diseases, autoimmune thyroid diseases, and gout disease. The invention provides also the combination for use in the treatment and/or prevention of cancer, in which deregulation of immune system takes place. The invention also relates to the therapeutic combination and to its use in the treatment or prevention of proteinuria.